About Repligen
Repligen is a company based in Waltham (United States) founded in 1981 by Paul Schimmel and Alexander Rich. The company has 1,780 employees as of December 31, 2024. Repligen has completed 11 acquisitions, including ARTeSYN, ATOLL-bio and Avitide. Repligen offers products and services including XCell ATF, KrosFlo TFF Systems, and OPUS Pre-packed Columns. Repligen operates in a competitive market with competitors including GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
- Headquarter Waltham, United States
- Employees 1780 as on 31 Dec, 2024
- Founders Paul Schimmel, Alexander Rich
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Repligen Corporation
-
Annual Revenue
$634.44 M (USD)0.33as on Dec 31, 2024
-
Net Profit
-$25.51 M (USD)-171.68as on Dec 31, 2024
-
EBITDA
$109.21 M (USD)-19.37as on Dec 31, 2024
-
Latest Funding Round
$238.59 M (USD), Post-IPO
Aug 01, 2017
- Investors
-
Employee Count
1780
as on Dec 31, 2024
-
Investments & Acquisitions
ARTeSYN
& 10 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Repligen
Repligen is a publicly listed company on the NASDAQ with ticker symbol RGEN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Repligen
Repligen offers a comprehensive portfolio of products and services, including XCell ATF, KrosFlo TFF Systems, and OPUS Pre-packed Columns.
Technology for cell culture intensification in bioprocessing
Systems for tangential flow filtration in drug manufacturing
Columns for efficient protein purification processes
People of Repligen
Unlock access to complete
Unlock access to complete
Software Development Team
61 people
Leadership Team
50 people
Product Management Team
28 people
Senior Team
27 people
Human Resources and Administration
21 people
Finance and Accounting
14 people
Sales and Marketing
9 people
Operations Team
8 people
Unlock access to complete
Funding Insights of Repligen
Investors in Repligen
Repligen has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Muscular Dystrophy Association.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
A community foundation dedicated to advancing cures for neuromuscular diseases.
|
Locked | Locked | Locked |
Investor details for Repligen
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Repligen
Repligen has strategically engaged in corporate development activities, having acquired 11 companies. Notable acquisitions include ARTeSYN, ATOLL-bio and Avitide.
Investment portfolio details for Repligen
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Tools for self-assembly based ordered nanostructures are developed.
|
Locked | Locked | 2014 | Locked | |
|
Disposable fluid management systems for bioprocessing are developed and manufactured.
|
Locked | Locked | 2012 | Locked | |
|
Affinity purification solutions are developed for biopharmaceutical applications.
|
Locked | Locked | 2012 | Locked |
Complete acquisition details for Repligen
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Repligen
Detailed financials for Repligen
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Repligen Comparisons
Peer comparison for Repligen
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Repligen
Repligen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as GSK, Avidity Biosciences, Sutro Biopharma, Antheia and Vividion Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of pharmaceuticals and vaccines for various therapeutic areas
|
|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Yeast cells are genetically engineered to produce medicinal products.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
CRISPR-engineered cell and gene therapies are developed for research applications.
|
Detailed competitors of Repligen
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Repligen
Complete news archive for Repligen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Repligen
Repligen was founded in 1981 and raised its 1st funding round 29 years after it was founded.
Repligen is headquartered in Waltham, United States. It is registered at Waltham, Massachusetts, United States.
Olivier Loeillot is the current CEO of Repligen.
As of Dec 31, 2024, the latest employee count at Repligen is 1,780.
Annual revenue of Repligen is $634.44M as on Dec 31, 2024.
Repligen was founded in 1981 and is headquartered in Waltham, United States. Bioprocessing technologies and reagents for the production of biologic drugs, including monoclonal antibodies, are developed and manufactured by the company. Key offerings include Protein A for antibody purification, growth factor products, and OPUS single-use chromatography columns. Operations focus on supporting purification processes in the biopharmaceutical sector.
Repligen's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Repligen offers XCell ATF, KrosFlo TFF Systems, and OPUS Pre-packed Columns.
Yes, Repligen is publicly traded on NASDAQ under the ticker symbol RGEN.
Repligen has 1 investor. Key investors include Muscular Dystrophy Association.
The ticker symbol of Repligen is RGEN on NASDAQ.